Back to mobile site

Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald As '26 Catalysts Already Credited

April 8, 2026 7:59 AM EDT Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $120.00 price target on Merck (NYSE: MRK).The analyst commented, "Our ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login